* Kite Pharma announces exclusive license with the National
Institutes of Health for fully human anti-cd19 chimeric antigen
receptor (car) product candidate to treat b-cell malignancies
Source text…
The post BRIEF-Kite Pharma announces license with NIH for anti-CD19 chimeric antigen receptor appeared first on NASDAQ.